Please check your internet connection and try again.
# Isoxsuprine hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator. Its mechanism of action is not fully understood but is thought to involve direct relaxation of vascular smooth muscle. It also has some beta-adrenergic agonist effects.
## Primary Indications
* Intermittent claudication due to peripheral vascular disease.
* Raynaud's disease.
* Achalasia (less common and evidence is limited).
## Adult Dosing
* **Intermittent Claudication/Peripheral Vascular Disease:** 10 mg to 20 mg orally every 3 to 4 times daily.
* **Achalasia:** 10 mg to 20 mg orally 3 times daily, 30 minutes before meals.
* **Maximum Dose:** Generally not specified, but doses exceeding 20 mg per administration are uncommon.
## Pediatric Dosing
There is no established pediatric dosing for isoxsuprine hydrochloride. Its use in children is generally not recommended due to lack of safety and efficacy data.
## Dose Adjustments
No specific dose adjustments are routinely recommended for hepatic or renal impairment. However, caution is advised in patients with severe disease.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Recent arterial hemorrhage with cardiovascular instability.
* Congenital or acquired heart defects.
* Tachyarrhythmias.
## Adverse Effects
* **Common:** Nausea, vomiting, gastric distress, dizziness, lightheadedness, weakness, flushing, rash.
* **Less Common:** Hypotension, tachycardia, palpitations, drowsiness.
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine may cause hypotension, potentially additive with antihypertensive agents.
* **Vasodilators:** Additive hypotensive effects may occur.
## Monitoring
* Blood pressure and heart rate.
* Symptoms of peripheral vascular disease (e.g., walking distance, pain).
* Signs of adverse effects.
## Clinical Pearls
* Onset of action is typically within 30 minutes to 1 hour, with peak effects at 1 to 2 hours.
* Duration of action is approximately 4 hours.
* Effectiveness in achalasia is variable and often considered secondary to other treatments.
* Discontinue if no improvement in symptoms is noted after a reasonable trial period (e.g., 1 month).
***
*Disclaimer: This information is intended for clinical professionals. Always verify current prescribing information, including FDA-approved indications, contraindications, warnings, precautions, and adverse reactions, with the official product labeling or a reliable drug information resource before initiating or modifying therapy.*
